This study aimed to explore lipoprotein metabolism in Obstructive Sleep Apnea (OSA) and the effects of continuous positive airway pressure (CPAP). We studied 15 men with severe OSA (apnea-hypopnea index, AHI ≥30 events/hour) and 12 age, body mass index and waist circumference-matched volunteers without OSA (AHI <5 events/hour). Carotid intima-media thickness (CIMT) was determined by a blind examiner. After 12 hours fasting, a triglyceride-rich chylomicron-like emulsion, labeled with [ 
Introduction
Obstructive sleep apnea (OSA) is a common clinical condition characterized by recurrent episodes of complete (apneas) or partial (hypopneas) obstructions of the upper airway leading to increased negative intrathoracic pressure, sleep fragmentation and chronic intermittent hypoxia (CIH) during sleep (1) . There is growing evidence that OSA is independently associated with cardiovascular events, including myocardial infarction and stroke (2) (3) (4) (5) . Mechanisms by which OSA leads to cardiovascular complications are not completely understood. Metabolic dysfunction may be involved in the increased risk of cardiovascular disease in patients with OSA (6) . It is known that OSA increases insulin resistance and worsens the control of type 2 diabetes (7-9), but the effects of OSA on lipid metabolism are not well established (10,11). We have previously utilized a mouse model and have shown that CIH, the hallmark of OSA, delayed the clearance of triglyceride-rich lipoproteins (TRLP) by inhibiting lipoprotein lipase (LpL) in the adipose tissue (12) . LpL catalyzes the lipolysis of TRLP, liversynthesized very low-density lipoproteins (VLDL) and chylomicrons produced in the intestine from dietary fats. In this model, LpL inactivation was induced by up-regulation of a powerful LpL inhibitor, angiopoietin-like protein 4 (Angptl4) (13) via hypoxia inducible factor 1 (HIF-1). The HIF-1-mediated increase in adipose Angptl4 and the resulting inhibition of LpL contributes to progression of atherosclerosis in apoE KO mice exposed to CIH (13) . The implications of these findings to TRLP metabolism in patients with OSA are unknown.
The hydrolysis of the TRLP triglycerides on the endothelial surface of capillaries, is a crucial process for energy storage by the organism. After lipolysis, the triglyceride-depleted remnants are removed by the liver. Defects in lipolysis of TRLP and in remnant removal predispose to development of atherosclerotic cardiovascular disease (14) (15) (16) (17) . Therefore, the aim of this study was to investigate whether the metabolism of TRLP is impaired in patients with OSA and whether disturbances in TRLP metabolism could be reversed by OSA treatment. Chylomicron-like emulsion labeled with radioactive triglycerides and cholesterol esters was used to assess the intravascular metabolism of TRLP in OSA 
Materials and Methods
During one-year period, we selected patients with severe OSA free of overt cardiovascular diseases (including hypertension, diabetes mellitus, cerebrovascular, aortic, cardiac disease, smoking habit as well as chronic use of medications) from the Sleep Laboratory, Heart Institute (InCor). Simultaneously, we invited healthy individuals from hospital staff after they completed a Berlin Questionnaire, indicating a low risk of OSA. Particular attention was paid to anthropometric characteristics to obtain two groups with a comparable age (±5 years), body mass index (BMI) (±3kg/m 2 ) and waist circumference (±5cm). Due to the lack of previous human data but based on previous experimental study (12) , we speculated the required sample size based on the assumption that patients with OSA will present 50% of the observed fractional clearance rate (FCR) of cholesterol ester and triglycerides in the matched controls.Using a significance level (alpha) of 5% and a power (1-beta) of 80%, we therefore estimated that at least 11 participants per group needed to be enrolled. Hypertension was carefully excluded based on the average of two or more properly measured, seated blood pressure readings on at least two office visits, according to current guidelines, by experienced physicians not involved in the study. We also considered out of 
Plasma kinetics of chylomicron-like emulsions
The chylomicron-like emulsion kinetic study was performed as previously described (19) .
Chylomicron-like emulsion mixture had triolein 76.5 ± 4.1%, free cholesterol 1.9±.3%, cholesteryloleate 11.2± 3.0% and phosphatidylcholine 10.4±1.3%; and size range from 80 to 110 nm. Lipid mixtures were emulsified by ultrasonic irradiation and purified by ultracentrifugation in density gradients. the ANACOMP software as previously described (19) . Conformity of the radioactivity dose administered to patients with the international regulations was demonstrated in our previous study (20) .
Carotid-intima media thickness (CIMT)
All participants had their vascular properties evaluated within 2 weeks after polysomnography. Carotidintima media thickness (CIMT) was made by an experienced observer (L.A.B.) blinded to the clinical condition of each participant. All measurements were performed with the patient in a recumbent position while awake. CIMT (in µm) were evaluated with a high-resolution echo-tracking system (Wall Track System, Medical Systems Arnhem, Oosterbeck, The Netherlands) coupled with a conventional twodimensional vascular echograph (Sigma 44 Kontrom Instruments, Watford, UK) equipped with a 7.5-MHz probe. As previously described (21) , measurements were performed on the right common carotid arteries 1 cm below the bifurcation at the site of the distal wall. CIMT was measured at the thickest point, Categorical variables were expressed by the frequency distribution, and their association was tested with likelihood ratio tests. A value of p <0.05 was considered significant.
Results
We screened one hundred and twenty consecutive patients who were diagnosed with severe OSA in our Sleep Laboratory over a one year-period. Twenty-five of them were found to be eligible for the study after excluding patients with comorbid diabetes, hypertension, heart failure, chronic kidney and liver disease as well as cigarette smokers and patients chronically using any medications. Fifteen patients agreed to participate and were enrolled in the study. A control group of 12 subjects without OSA (confirmed by overnight polysomnography) was selected out of 20 healthy volunteers matched by age (±5years), body mass index (±3kg/m 2 ) and waist circumference (±5cm) with low risk for OSA by Berlin Questionnaire (24). OSA patients also showed a trend for higher plasma noradrenaline levels. As expected from the design, sleep apnea differed between the groups. In addition, OSA was associated with higher CIMT values.
Figures 1A and 1B show the plasma decay curves of radioactively labeled cholesterol esters and triglycerides in OSA patients and control subjects. Apparently, the decay curves did not markedly differ CPAP treatment increased fivefold the triglyceride-FCR, from 0.00650.0088 to 0.03020.0245 min -1 ( Figure 1F ). The increase in the cholesterol ester FCR was not statistically significant ( Figure 1E ). Multivariate analysis (Table 4) showed that BMI and the presence of OSA were independently associated with cholesterol ester-FCR. White race, BMI, waist circumference and the presence of OSA were independently associated with triglycerides-FCR.
Discussion
This study examined the effects of OSA on the metabolism of TRLP in subjects. We found that Chylomicronemia elicits atherosclerosis in mice (26) . Chylomicron remnants induce macrophage foam cell formation and the development of the atherosclerotic plaque (27) . Postprandial hypertriglyceridemia confers risk of myocardial infarction, ischemic heart disease, stroke and death (17, 28, 29) . Our study has some strengths and limitations. The main strengths include: 1) we performed full polysomnography, considered the gold standard method for diagnosing OSA; 2) In order to understand the relative role of OSA on lipid clearance in humans, we carefully selected patients and appropriate matched controls with no substantial confounding factor such as hypertension, smoking, diabetes and regular use of any medication; 3) the robust evaluation of TRLP clearance. In the emulsion method used in this study to evaluate the TRLP intravascular metabolism, potential confounders such as differences in intestinal motility, microbiota and other factors affection fat absorption are bypassed. The chylomicron-like emulsions that are devoid of proteins acquire apolipoproteins from the native plasma lipoproteins.
Acquisition of apoC II allows lipolysis of the emulsion particles by LpL and of apoE allows remnant removal by hepatic receptors that recognize this apolipoprotein (35) . After injection of the doublylabeled chylomicron-like emulsions into the plasma compartment, the plasma decay curves of radioactive cholesteryl-esters that are not independently removed from the emulsion particles stand for the removal of remnants. On the other hand, the triglyceride curves mirror the lipolysis process chylomicrons undergo in the plasma compartment. In this approach, artificially-made emulsions with composition similar to that of lymph chylomicrons and doubly labeled with radioactive cholesteryl esters and triglycerides are intravenously injected. Therefore, the chylomicron-like emulsion is a straightforward and precise method to evaluate TRLP, allowing the analysis of plasma kinetics and simultaneous discrimination of the two major processes occurring in TRLP metabolism, namely lipolysis by LpL and the removal of the remnants by the liver. The following limitations should be acknowledged: firstly, results from this study were limited to male patients with severe OSA and no significant comorbidities. Therefore, this finding may be not true for mild or moderate OSA. While interesting to figure out the relative role of OSA, the exclusion of females, smokers and patients with diabetes, hypertension as well as coronary artery disease may limit generalizability. Secondly, we did not perform measurement of LpL, a key enzyme involved in the lipid metabolism. There are some concerns and pitfalls in getting peripheral blood as a reliable and representative marker of LpL activity at tissue level. Thirdly, liver fat content may play role in triglyceride clearance (36) and was not addressed in the current study. Finally, our results are derived from a cross sectional study and the associations must be interpreted with caution. The sample size was calculated based on the comparisons of OSA and matched controls. However, it is reassuring that in a sub-group in whom OSA was properly treated with CPAP improved fivefold triglyceride-FCR. The lack of significance increase in the cholesterol ester-FCR may be related to the small sample size, rather than a lack of effect.
In conclusion, our results establish that OSA leads to pro-atherogenic disturbances of the TRLP metabolism. In this regard, severe OSA patients showed delayed removal of remnants and decreased lipolysis of TRLP. As shown in previous studies, those defects of TRLP metabolism are associated not only with the presence of coronary artery disease but also with the severity and the incidence of the complications of this disease. 
